CN120102879A - 检测胃肠道疾病的组合物和方法 - Google Patents
检测胃肠道疾病的组合物和方法 Download PDFInfo
- Publication number
- CN120102879A CN120102879A CN202510261116.9A CN202510261116A CN120102879A CN 120102879 A CN120102879 A CN 120102879A CN 202510261116 A CN202510261116 A CN 202510261116A CN 120102879 A CN120102879 A CN 120102879A
- Authority
- CN
- China
- Prior art keywords
- iap
- nec
- activity
- protein
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Husbandry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/267,120 US11493515B2 (en) | 2016-08-04 | 2019-02-04 | Compositions and methods to detect gastrointestinal disease |
| US16/267,120 | 2019-02-04 | ||
| CN202080027193.3A CN113645846B (zh) | 2019-02-04 | 2020-02-04 | 检测胃肠道疾病的组合物和方法 |
| PCT/US2020/016646 WO2020163381A1 (fr) | 2019-02-04 | 2020-02-04 | Compositions et procédés pour détecter une maladie gastro-intestinale |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080027193.3A Division CN113645846B (zh) | 2019-02-04 | 2020-02-04 | 检测胃肠道疾病的组合物和方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN120102879A true CN120102879A (zh) | 2025-06-06 |
Family
ID=83366685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510261116.9A Pending CN120102879A (zh) | 2019-02-04 | 2020-02-04 | 检测胃肠道疾病的组合物和方法 |
| CN202080027193.3A Active CN113645846B (zh) | 2019-02-04 | 2020-02-04 | 检测胃肠道疾病的组合物和方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080027193.3A Active CN113645846B (zh) | 2019-02-04 | 2020-02-04 | 检测胃肠道疾病的组合物和方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3920713A4 (fr) |
| CN (2) | CN120102879A (fr) |
| AU (1) | AU2020217717B2 (fr) |
| CA (1) | CA3128826A1 (fr) |
| WO (1) | WO2020163381A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120673884A (zh) * | 2025-08-20 | 2025-09-19 | 温州医科大学 | 基于ai的克林霉素磷酸酯加工水解优化方法及系统 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114113624B (zh) * | 2020-08-28 | 2024-08-16 | 香港城市大学深圳研究院 | 利用免疫球蛋白关联蛋白质组开发疾病标志物的方法及装置 |
| US11741686B2 (en) | 2020-12-01 | 2023-08-29 | Raytheon Company | System and method for processing facility image data |
| WO2023141560A2 (fr) * | 2022-01-20 | 2023-07-27 | Synthetic Biologics, Inc. | Phosphatase alcaline destinée à être utilisée en oncologie |
| CN116662798B (zh) * | 2023-04-23 | 2026-02-24 | 迪辅乐生物(上海)有限公司 | 基于肠型分型的微生物组合物、过敏预测模型的构建方法及其模型和应用 |
| WO2025075652A1 (fr) * | 2023-10-06 | 2025-04-10 | DeLorean Artificial Intelligence, Inc. | Système et méthode de gestion de soins médicaux |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006026383A2 (fr) * | 2004-08-26 | 2006-03-09 | Strategic Health Decisions, Inc. | Systeme pour optimiser les strategies de traitement au moyen d'un systeme d'evaluation specifique du patient |
| US20140162370A1 (en) * | 2011-06-14 | 2014-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Urine biomarkers for necrotizing enterocolitis and sepsis |
| US10950353B2 (en) * | 2013-09-20 | 2021-03-16 | Georgia Tech Research Corporation | Systems and methods for disease progression modeling |
| BR112017014419A2 (pt) * | 2015-01-09 | 2018-01-16 | S Malo Madhu | diagnose e tratamento de diabetes incipiente |
| WO2018027179A1 (fr) * | 2016-08-04 | 2018-02-08 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions et méthodes pour détecter une maladie gastro-intestinale |
| CN108061556B (zh) * | 2017-10-18 | 2021-07-09 | 广州傲胜机器人科技有限公司 | 一种基于隐马尔可夫模型的地图匹配方法 |
-
2020
- 2020-02-04 WO PCT/US2020/016646 patent/WO2020163381A1/fr not_active Ceased
- 2020-02-04 CN CN202510261116.9A patent/CN120102879A/zh active Pending
- 2020-02-04 CN CN202080027193.3A patent/CN113645846B/zh active Active
- 2020-02-04 CA CA3128826A patent/CA3128826A1/fr active Pending
- 2020-02-04 EP EP20752596.5A patent/EP3920713A4/fr not_active Withdrawn
- 2020-02-04 AU AU2020217717A patent/AU2020217717B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120673884A (zh) * | 2025-08-20 | 2025-09-19 | 温州医科大学 | 基于ai的克林霉素磷酸酯加工水解优化方法及系统 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113645846B (zh) | 2025-02-25 |
| CN113645846A (zh) | 2021-11-12 |
| EP3920713A4 (fr) | 2022-11-09 |
| EP3920713A1 (fr) | 2021-12-15 |
| AU2020217717B2 (en) | 2026-03-12 |
| CA3128826A1 (fr) | 2020-08-13 |
| WO2020163381A1 (fr) | 2020-08-13 |
| AU2020217717A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113645846B (zh) | 检测胃肠道疾病的组合物和方法 | |
| Chatzicostas et al. | Balthazar computed tomography severity index is superior to Ranson criteria and APACHE II and III scoring systems in predicting acute pancreatitis outcome | |
| US11493515B2 (en) | Compositions and methods to detect gastrointestinal disease | |
| US8361732B2 (en) | Combination of sPLA2 activity and oxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event | |
| Lin et al. | Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients | |
| Mori et al. | Prognostic implications of the global leadership initiative on malnutrition criteria as a routine assessment modality for malnutrition in hospitalized patients at a university hospital | |
| Yamout et al. | Peritoneal and plasma D‐lactate concentrations in horses with colic | |
| Dong et al. | Hyperlipemia pancreatitis onset time affects the association between elevated serum triglyceride levels and disease severity | |
| US9417247B2 (en) | Human autoantibodies specific for PAD3 which are cross-reactive with PAD4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases | |
| Patel et al. | Clinical data do not reliably predict duodenal histology at follow-up in celiac disease: a 13 center correlative study | |
| Benito et al. | Lack of value of midregional pro-adrenomedullin and C-terminal pro-endothelin-1 for prediction of severe bacterial infections in infants with fever without a source | |
| Sharif et al. | Low serum albumin concentration predicts the need for surgical intervention in neonates with necrotizing enterocolitis | |
| US11953501B2 (en) | Compositions and methods to detect gastrointestinal disease | |
| US20230258660A1 (en) | A method for distinguishing healthy individuals from individuals having infectious or inflammatory conditions | |
| Manzoor et al. | Association of serum biochemical panel with mineralogical composition of kidney stone in India | |
| US20240393333A1 (en) | Compositions and methods to detect gastrointestinal disease | |
| US12282019B2 (en) | Compositions and methods to detect gastrointestinal disease | |
| Dzudzor et al. | Serum 25‐hydroxyvitamin D and hyaluronic acid levels as markers of fibrosis in patients with chronic liver disease at the main tertiary referral hospital in Ghana: A case‐control study design | |
| EP3311164B1 (fr) | Méthodes et compositions pour le diagnostic et le pronostic de l'appendicite et la différenciation des causes de la douleur abdominale | |
| Firouzi et al. | A cross-sectional study on the correlation between blood phosphorus level with sepsis and associated prognostic factors in neonates | |
| Fawzy et al. | Non-invasive follow-up of Egyptian patients infected with Helicobacter pylori by quantification of H. pylori circulating antigen in serum using ELISA | |
| Yadav et al. | Diagnostic Characteristics of Procalcitonin and Phospholipase A2 in Patients with Sepsis | |
| Tramontano et al. | Trend of C-Reactive protein after colorectal surgery may increase predictive value of anastomotic leak: a prospective analysis | |
| Ming et al. | U-shaped association between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol and risk of cholelithiasis: a cohort study | |
| Jessee | Stool studies: tried, true, and new |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |